[{"orgOrder":0,"company":"Celonic","sponsor":"Airway Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"AT-100","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Celonic \/ Airway Therapeutics"},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ Intravacc"},{"orgOrder":0,"company":"Celonic","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"mRNA vaccines","moa":"T Cell activatior","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Celonic \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Celonic \/ CureVac"}]

Find Clinical Drug Pipeline Developments & Deals by Celonic

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021.

                          Brand Name : CVnCoV

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 30, 2021

                          Lead Product(s) : mRNA vaccines

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : CureVac

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 29, 2020

                          Lead Product(s) : Covid-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Intravacc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 20, 2020

                          Lead Product(s) : AT-100

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Airway Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank